These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27084416)

  • 21. Regulating Off-Label Promotion - A Critical Test.
    Robertson C; Kesselheim AS
    N Engl J Med; 2016 Dec; 375(24):2313-2315. PubMed ID: 27805841
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA off-track on off-label drug promotion.
    Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
    [No Abstract]   [Full Text] [Related]  

  • 24. Pfizer settles largest ever fraud suit for off-label promotion.
    Ratner M
    Nat Biotechnol; 2009 Nov; 27(11):961-2. PubMed ID: 19898429
    [No Abstract]   [Full Text] [Related]  

  • 25. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 26. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 27. The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
    Sharfstein JM; Charo A
    JAMA; 2015 Nov; 314(17):1795-6. PubMed ID: 26367520
    [No Abstract]   [Full Text] [Related]  

  • 28. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 29. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead.
    Hayes TA
    Clin Pharmacol Ther; 1998 Jun; 63(6):607-16. PubMed ID: 9663174
    [No Abstract]   [Full Text] [Related]  

  • 30. So you want to market a food and to make health-related claims--how far can you go? What rules of law will govern the claims you want to make?
    McNamara SH
    Food Drug Law J; 1998; 53(3):421-36. PubMed ID: 10346720
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 32. Off label drug promotion.
    Body Posit; 1998 Oct; 11(10):11. PubMed ID: 11365909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 34. The FDA Export Reform and Enhancement Act of 1996: the FDA's new extraterritorial authority over labeling and promotional practices.
    Helmanis AM
    Food Drug Law J; 1996; 51(4):631-5. PubMed ID: 11797732
    [No Abstract]   [Full Text] [Related]  

  • 35. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 36. Regulation of pharmacoeconomics and outcomes research.
    Radensky P
    Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
    [No Abstract]   [Full Text] [Related]  

  • 37. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
    Weeks EA
    Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
    [No Abstract]   [Full Text] [Related]  

  • 38. Troublesome inconsistencies in the federal regulation of pyrethrin-based shampoos.
    Surgan MH
    West J Med; 2001 Mar; 174(3):169. PubMed ID: 11238343
    [No Abstract]   [Full Text] [Related]  

  • 39. The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.
    Sinha MS; Kesselheim AS
    PLoS Med; 2018 May; 15(5):e1002564. PubMed ID: 29738523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Off-Label Marketing's Audiences: The 21
    Halabi SF
    Am J Law Med; 2018 May; 44(2-3):181-196. PubMed ID: 30106659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.